PPIDT00165
Drug Information
| Name | Trastuzumab emtansine |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB05773 |
| Type | biotech |
| Indication | Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous; Parenteral |
100 MG
|
| Injection, powder, for solution | Intravenous; Parenteral |
160 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
20 mg/1mL
|
| Powder, for solution | Intravenous |
100 mg / vial
|
| Powder, for solution | Intravenous |
160 mg / vial
|
| Solution | Intravenous |
106.000 mg
|
| Injection, solution | Intravenous |
100 mg
|
| Injection, solution | Intravenous |
160 mg
|
| Injection, powder, for solution | Intravenous |
20 mg/mL
|
| Injection, powder, for solution | Intravenous |
100 mg
|
| Injection, powder, for solution | Intravenous |
160 mg
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P04626 | ERBB2 | Receptor tyrosine-protein kinase erbB-2 | Homo sapiens | antibody | Link |
| enzyme | P08684 | CYP3A4 | Cytochrome P450 3A4 | Homo sapiens | substrate | Link |
| enzyme | P20815 | CYP3A5 | Cytochrome P450 3A5 | Homo sapiens | substrate | Link |
| transporter | P08183 | ABCB1 | ATP-dependent translocase ABCB1 | Homo sapiens | substrate | Link |